A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M; Investigational New Drugs, 2012, vol. 30, issue 3, p 1088, ISSN 15730646. ISBN 15730646.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef